- Home
- FCO vs ASMB Comparison
FCO vs ASMB Comparison
Compare FCO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- ASMB
- Stock Information
- Founded
- FCO 1991
- ASMB 2005
- Country
- FCO United Kingdom
- ASMB United States
- Employees
- FCO N/A
- ASMB N/A
- Industry
- FCO Investment Managers
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- ASMB Health Care
- Exchange
- FCO Nasdaq
- ASMB Nasdaq
- Market Cap
- FCO 78.3M
- ASMB 76.9M
- IPO Year
- FCO N/A
- ASMB 2010
- Fundamental
- Price
- FCO $6.11
- ASMB $12.48
- Analyst Decision
- FCO
- ASMB Strong Buy
- Analyst Count
- FCO 0
- ASMB 3
- Target Price
- FCO N/A
- ASMB $33.00
- AVG Volume (30 Days)
- FCO 100.1K
- ASMB 22.3K
- Earning Date
- FCO 01-01-0001
- ASMB 05-20-2025
- Dividend Yield
- FCO 14.96%
- ASMB N/A
- EPS Growth
- FCO N/A
- ASMB N/A
- EPS
- FCO 0.43
- ASMB N/A
- Revenue
- FCO N/A
- ASMB $28,520,000.00
- Revenue This Year
- FCO N/A
- ASMB $10.82
- Revenue Next Year
- FCO N/A
- ASMB N/A
- P/E Ratio
- FCO $12.30
- ASMB N/A
- Revenue Growth
- FCO N/A
- ASMB 298.16
- 52 Week Low
- FCO $4.73
- ASMB $7.75
- 52 Week High
- FCO $6.63
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- FCO 62.53
- ASMB 58.52
- Support Level
- FCO $5.96
- ASMB $11.64
- Resistance Level
- FCO $6.25
- ASMB $14.80
- Average True Range (ATR)
- FCO 0.13
- ASMB 0.83
- MACD
- FCO 0.04
- ASMB 0.18
- Stochastic Oscillator
- FCO 78.57
- ASMB 53.71
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.